ANIK - Anika Therapeutics, Inc.
IEX Last Trade
16.6
0.040 0.241%
Share volume: 1,898
Last Updated: Thu 26 Dec 2024 08:27:16 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$16.56
0.04
0.24%
Fundamental analysis
8%
Profitability
0%
Dept financing
5%
Liquidity
70%
Performance
1%
Performance
5 Days
0.62%
1 Month
-7.84%
3 Months
-33.70%
6 Months
-36.34%
1 Year
-28.38%
2 Year
-42.03%
Key data
Stock price
$16.60
DAY RANGE
$16.30 - $16.72
52 WEEK RANGE
$16.44 - $29.11
52 WEEK CHANGE
-$27.87
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Cheryl R. Blanchard
Region: US
Website: anikatherapeutics.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: anikatherapeutics.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Anika Therapeutics, Inc. creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.
Recent news